<p>CareDx, Inc.（纳斯达克代码：CDNA - 获取免费报告）的股票在目前覆盖该公司的九家券商中获得了 “持有” 的共识推荐，MarketBeat Ratings 报告称。五位股票研究分析师对该股票给予了持有推荐，四位则给予了买入推荐。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价格为 26.6667 美元。</p>
<p>几位分析师对该股票发表了看法。William Blair 在 8 月 26 日的研究报告中开始覆盖 CareDx 的股票。他们对该公司的评级为 “市场表现”。Weiss Ratings 在 12 月 15 日的报告中重申了对 CareDx 股票的 “持有（c-）” 评级。富国银行将 CareDx 股票的目标价格从 14.00 美元提高到 18.00 美元，并在 12 月 15 日的研究报告中给予该股票 “等权重” 评级。Zacks Research 在 11 月 18 日的报告中将 CareDx 的评级从 “强烈卖出” 上调至 “持有”。最后，Wall Street Zen 在周日的研究报告中将 CareDx 的评级从 “持有” 上调至 “买入”。</p>
<p><strong>获取我们最新的 CareDx 股票报告</strong></p>
<h2>对 CareDx 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近修改了对 CDNA 的持仓。Bamco Inc. NY 在第三季度将其在 CareDx 的持仓增加了 29.5%。Bamco Inc. NY 目前拥有 3,155,180 股该公司的股票，价值 45,876,000 美元，在此期间又收购了 719,523 股。Deerfield Management Company L.P. 在第三季度获得了 CareDx 的新头寸，价值约为 31,857,000 美元。Braidwell LP 在第三季度购买了 CareDx 的新头寸，价值约为 31,738,000 美元。ARK Investment Management LLC 在第三季度将其在 CareDx 的股份增加了 3.4%。ARK Investment Management LLC 目前拥有 2,170,625 股该公司的股票，价值 31,561,000 美元，在此期间又购买了 70,468 股。最后，Ophir Asset Management Pty Ltd 在第二季度将其在 CareDx 的持仓增加了 17.0%。Ophir Asset Management Pty Ltd 目前拥有 1,892,994 股该公司的股票，价值 36,989,000 美元，在上个季度又购买了 274,625 股。</p>
<h2>CareDx 股票表现</h2>
<p>CareDx 股票周一开盘价为 19.45 美元。CareDx 的一年最低价为 10.96 美元，一年最高价为 25.95 美元。该公司的 50 日简单移动平均线为 16.69 美元，200 日简单移动平均线为 15.81 美元。该公司的市值为 10 亿美元，市盈率为 16.34，贝塔值为 2.54。</p>
<p>CareDx（纳斯达克代码：CDNA - 获取免费报告）最近在 11 月 4 日公布了季度财报。该公司报告每股收益（EPS）为 0.28 美元，超出市场共识预期的 0.13 美元，超出幅度为 0.15 美元。该公司季度收入为 1 亿 006 万美元，超过分析师预期的 9,525 万美元。CareDx 的股本回报率为 20.15%，净利润率为 19.65%。与去年同期相比，CareDx 本季度的收入增长了 20.7%。在去年同期，该公司每股收益为（0.14）美元。平均而言，股票分析师预测 CareDx 本年度每股收益为-0.9 美元。</p>
<h2>关于 CareDx</h2>
<p>（获取免费报告）</p>
<p>CareDx, Inc.（纳斯达克代码：CDNA）是一家专注于移植患者护理的精准诊断公司。该公司开发和商业化非侵入性检测，旨在检测器官移植排斥和感染风险，帮助医生在移植后的管理过程中做出明智的决策。</p>
<p>该公司的核心产品组合包括 AlloMap®，一种用于心脏移植受者的基因表达分析测试，以及 AlloSure®，一种主要用于肾脏移植监测的供体衍生无细胞 DNA 检测。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 CareDx</li>
<li>100 万美元在退休后能维持多久？</li>
<li>黄金警报</li>
<li>比特币下跌，但你的收入即将暴涨</li>
<li>这个 40 年的掩盖即将结束</li>
<li>富人如何退休</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0ROQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0ROQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 CareDx 吗？</h2>
<p>在你考虑 CareDx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 CareDx 并不在名单上。</p>
<p>虽然 CareDx 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CDNA

<p>CareDx, Inc.（纳斯达克代码：CDNA）获得了九家券商的一致 “持有” 评级。五位分析师建议持有，而四位则建议买入。12 个月的平均目标价格为 26.67 美元。最近的分析师行动包括威廉·布莱尔的 “市场表现” 评级和富国银行将目标价格上调至 18.00 美元。对冲基金已调整其持仓，Bamco Inc. NY 等公司进行了重大投资。CareDx 的股票开盘价为 19.45 美元，市值为 10 亿美元。该公司专注于移植患者的诊断，产品包括 AlloMap®和 AlloSure®</p>

<p>Shares of CareDx, Inc. (NASDAQ:CDNA - Get Free Report) have been given a consensus recommendation of &#34;Hold&#34; by the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $26.6667.</p>
<div class="lb-trans"><p>CareDx, Inc.（纳斯达克代码：CDNA - 获取免费报告）的股票在目前覆盖该公司的九家券商中获得了 “持有” 的共识推荐，MarketBeat Ratings 报告称。五位股票研究分析师对该股票给予了持有推荐，四位则给予了买入推荐。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价格为 26.6667 美元。</p>
</div><p>Several analysts have weighed in on the stock. William Blair initiated coverage on shares of CareDx in a research note on Tuesday, August 26th. They set a &#34;market perform&#34; rating for the company. Weiss Ratings reaffirmed a &#34;hold (c-)&#34; rating on shares of CareDx in a report on Monday, December 15th. Wells Fargo &amp; Company increased their price objective on shares of CareDx from $14.00 to $18.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Monday, December 15th. Zacks Research raised CareDx from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, November 18th. Finally, Wall Street Zen upgraded CareDx from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Sunday.</p>
<div class="lb-trans"><p>几位分析师对该股票发表了看法。William Blair 在 8 月 26 日的研究报告中开始覆盖 CareDx 的股票。他们对该公司的评级为 “市场表现”。Weiss Ratings 在 12 月 15 日的报告中重申了对 CareDx 股票的 “持有（c-）” 评级。富国银行将 CareDx 股票的目标价格从 14.00 美元提高到 18.00 美元，并在 12 月 15 日的研究报告中给予该股票 “等权重” 评级。Zacks Research 在 11 月 18 日的报告中将 CareDx 的评级从 “强烈卖出” 上调至 “持有”。最后，Wall Street Zen 在周日的研究报告中将 CareDx 的评级从 “持有” 上调至 “买入”。</p>
</div><p><strong>Get Our Latest Stock Report on CareDx</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 CareDx 股票报告</strong></p>
</div><h2>Hedge Funds Weigh In On CareDx</h2>
<div class="lb-trans"><h2>对 CareDx 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of CDNA. Bamco Inc. NY increased its holdings in shares of CareDx by 29.5% in the 3rd quarter. Bamco Inc. NY now owns 3,155,180 shares of the company's stock worth $45,876,000 after acquiring an additional 719,523 shares during the period. Deerfield Management Company L.P. acquired a new position in CareDx during the 3rd quarter valued at about $31,857,000. Braidwell LP bought a new position in CareDx in the 3rd quarter worth about $31,738,000. ARK Investment Management LLC increased its stake in shares of CareDx by 3.4% in the third quarter. ARK Investment Management LLC now owns 2,170,625 shares of the company's stock valued at $31,561,000 after purchasing an additional 70,468 shares during the period. Finally, Ophir Asset Management Pty Ltd raised its holdings in shares of CareDx by 17.0% during the second quarter. Ophir Asset Management Pty Ltd now owns 1,892,994 shares of the company's stock valued at $36,989,000 after buying an additional 274,625 shares during the last quarter.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近修改了对 CDNA 的持仓。Bamco Inc. NY 在第三季度将其在 CareDx 的持仓增加了 29.5%。Bamco Inc. NY 目前拥有 3,155,180 股该公司的股票，价值 45,876,000 美元，在此期间又收购了 719,523 股。Deerfield Management Company L.P. 在第三季度获得了 CareDx 的新头寸，价值约为 31,857,000 美元。Braidwell LP 在第三季度购买了 CareDx 的新头寸，价值约为 31,738,000 美元。ARK Investment Management LLC 在第三季度将其在 CareDx 的股份增加了 3.4%。ARK Investment Management LLC 目前拥有 2,170,625 股该公司的股票，价值 31,561,000 美元，在此期间又购买了 70,468 股。最后，Ophir Asset Management Pty Ltd 在第二季度将其在 CareDx 的持仓增加了 17.0%。Ophir Asset Management Pty Ltd 目前拥有 1,892,994 股该公司的股票，价值 36,989,000 美元，在上个季度又购买了 274,625 股。</p>
</div><h2>CareDx Stock Performance</h2>
<div class="lb-trans"><h2>CareDx 股票表现</h2>
</div><p>Shares of CareDx stock opened at $19.45 on Monday. CareDx has a 1 year low of $10.96 and a 1 year high of $25.95. The firm's 50-day simple moving average is $16.69 and its 200-day simple moving average is $15.81. The firm has a market cap of $1.00 billion, a PE ratio of 16.34 and a beta of 2.54.</p>
<div class="lb-trans"><p>CareDx 股票周一开盘价为 19.45 美元。CareDx 的一年最低价为 10.96 美元，一年最高价为 25.95 美元。该公司的 50 日简单移动平均线为 16.69 美元，200 日简单移动平均线为 15.81 美元。该公司的市值为 10 亿美元，市盈率为 16.34，贝塔值为 2.54。</p>
</div><p>CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.15. The firm had revenue of $100.06 million for the quarter, compared to analysts' expectations of $95.25 million. CareDx had a return on equity of 20.15% and a net margin of 19.65%.CareDx's revenue for the quarter was up 20.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.14) earnings per share. On average, equities analysts predict that CareDx will post -0.9 earnings per share for the current year.</p>
<div class="lb-trans"><p>CareDx（纳斯达克代码：CDNA - 获取免费报告）最近在 11 月 4 日公布了季度财报。该公司报告每股收益（EPS）为 0.28 美元，超出市场共识预期的 0.13 美元，超出幅度为 0.15 美元。该公司季度收入为 1 亿 006 万美元，超过分析师预期的 9,525 万美元。CareDx 的股本回报率为 20.15%，净利润率为 19.65%。与去年同期相比，CareDx 本季度的收入增长了 20.7%。在去年同期，该公司每股收益为（0.14）美元。平均而言，股票分析师预测 CareDx 本年度每股收益为-0.9 美元。</p>
</div><h2>About CareDx</h2>
<div class="lb-trans"><h2>关于 CareDx</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CareDx, Inc NASDAQ: CDNA is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.</p>
<div class="lb-trans"><p>CareDx, Inc.（纳斯达克代码：CDNA）是一家专注于移植患者护理的精准诊断公司。该公司开发和商业化非侵入性检测，旨在检测器官移植排斥和感染风险，帮助医生在移植后的管理过程中做出明智的决策。</p>
</div><p>The company's core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.</p>
<div class="lb-trans"><p>该公司的核心产品组合包括 AlloMap®，一种用于心脏移植受者的基因表达分析测试，以及 AlloSure®，一种主要用于肾脏移植监测的供体衍生无细胞 DNA 检测。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than CareDx</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>GOLD ALERT</li>
<li>Bitcoin is down but your income is about to explode</li>
<li>This 40-year cover-up is ending</li>
<li>How the Rich Retire</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 CareDx</li>
<li>100 万美元在退休后能维持多久？</li>
<li>黄金警报</li>
<li>比特币下跌，但你的收入即将暴涨</li>
<li>这个 40 年的掩盖即将结束</li>
<li>富人如何退休</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0ROQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CDNA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CareDx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 CareDx 吗？</h2>
</div><p>Before you consider CareDx, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 CareDx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 CareDx 并不在名单上。</p>
</div><p>While CareDx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CareDx 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

CareDx, Inc.（纳斯达克股票代码：CDNA）被券商一致评级为 “持有”